Gefitinib with Chemotherapy in EGFR-Mutated Lung Cancer
1. The median overall survival was 17.6 months in the gefitinib group vs 27.5 months in the...
Read More
Oncology
#VisualAbstract: Sentinel-node biopsy only is noninferior to completion of axillary lymph node dissection in breast cancer with sentinel-node metastases
1. The hazard ratio for recurrence or death comparing sentinel node biopsy only to completion...
Read More
Overall Survival Improved with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
1. The overall survival at 48 months was 91.2% in the pembrolizumab group vs 86.0% in the placebo...
Read More
Mitoxantrone is superior to liposomal daunorubicin in MRD (measurable residual disease)-guided treatment of AML in pediatric cases
1. Mitoxantrone enhances five-year event-free survival over liposomal daunorubicin in MRD-guided...
Read More
Novel Oral Synthetic Genistein Nanosuspension May Protect Against Negative Effects Of Radiation Therapy In Lung Cancer
BIO 300 use led to reduced levels of a proinflammatory/profibrotic cytokine associated with lung...
Read More
Neoadjuvant chemotherapy does not appear to significantly improve disease-free survival in patients with locally advanced colon cancer
1. When compared to upfront surgery, neoadjuvant chemotherapy using mFOLFOX or CAPOX did not...
Read More
Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases
1. The hazard ratio for recurrence or death comparing sentinel node biopsy only to completion...
Read More
#VisualAbstract: Imetelstat improves blood transfusion independence in lower-risk myelodysplastic syndromes
1. Significantly more patients in the imetelstat group achieved RBC transfusion independence at 8...
Read More
#VisualAbstract: Pazopanib does not improve disease-free survival post-metastasectomy for renal cell carcinoma patients
1. Pazopanib did not improve disease-free survival in post-metastasectomy renal cell carcinoma...
Read More
#VisualAbstract: Iptacopan improves hematologic and clinical outcomes in paroxysmal nocturnal hemoglobinuria
1. In two clinical trials, iptacopan in patients with paroxysmal nocturnal hemoglobinuria (PNH)...
Read More
Though associated with rising costs, the majority of publicly-funded cancer medications included in Ontario, Canada are those with substantial survival benefit
1. Roughly 65% of the cancer medication budget is allocated to treatments that provide improvement...
Read More
Neoadjuvant Dual vs Single Checkpoint Inhibitors in High-Risk Melanoma
1. The pathological response rate had an OR of 3.16 when comparing neoadjuvant dual vs single...
Read More
#VisualAbstract: Ribociclib Improves Invasive Disease-Free Survival in Patients with Early Breast Cancer
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No...
Read More
#VisualAbstract: Preoperative breast MRI may reduce need for adjuvant radiotherapy for women with unifocal breast cancer
1. There were similar rates of ipsilateral invasive recurrence among the postoperative adjuvant...
Read More
Individualized cancer mRNA-based cancer therapy shows benefit in patients with high-risk melanoma on immunotherapy
1. 18-month recurrence-free survival was significantly greater in the combination therapy group...
Read More
Pazopanib does not improve disease-free survival post-metastasectomy for renal cell carcinoma patients
1. Pazopanib did not improve disease-free survival in post-metastasectomy renal cell carcinoma...
Read More
Neoadjuvant Chemoimmunotherapy for Lung Cancer – A Meta-Analysis
1. The overall survival had a significant hazard ratio (0.65) when comparing neoadjuvant...
Read More
Adding ribociclib to endocrine therapy appears to improve invasive disease-free survival in patients with early breast cancer
1. Invasive disease-free survival was significantly higher in patients receiving adjuvant...
Read More
Venetoclax monotherapy effectively treats relapsed or refractory chronic lymphocytic leukemia
1. VENICE-1 observed high response rates (complete or partial remission) in both BCRi-naïve and...
Read More
A cell-free, blood-based DNA screening test for colorectal cancer compared to colonoscopy
1. 83.1% of patients with confirmed colorectal cancer had a positive cfDNA test meeting the...
Read More